Pharmacovigilance As An Important Tool For Reducing Adverse Drug Reactions.
Keywords:
Pharmacovigilance, ADR, Adverse drug reactions, Medicine Safety etcAbstract
Before a drug being marketed or made available to the patient clinical trials of the drugs is carried out to check its safety and efficacy, whether it produces any adverse event or serious adverse drug reactions (SADRs), how well the drug works, it’s benefit-harmful profile, Is it producing more harmful effect than benefits, by the manufacturer and If a drug passes the clinical trials it can be marketed.
Despite these clinical trials various unexpected and serious adverse drug reactions (SADRs) repeatedly occur after marketing. This study of adverse drug reactions (ADRs) is pharmacovigilance.
Pharmacovigilance is the pharmacological science relating to the detection, assessment, understanding and prevention of adverse effects particularly long term and short-term side effects of medicines8.
The pharmacovigilance aim is to provide the benefit, effectiveness, safety, harm, risks of medicines on patients, as well as safeguard the rights, safety and wellbeing of all patients in relation to use of medicines.
If the drug marketed is found to contain significant toxic effect or serious adverse drug reactions (SADRs) the drug is withdrawn from market or restricted to certain uses. If it is safe, then marketed overall.
The international collaboration in the field of pharmacovigilance involves WHO international drug monitoring program which record and report adverse effect of drugs in patient.
The proper database management of pharmacovigilance study to meet public expectations and the demands of modern public health1..
Downloads
References
Maqbool M, Dar MA, Rasool S, Bhat AU, Geer MI, Drug safety and Pharmacovigilance: An overview, Journal of Drug Delivery and Therapeutics. 2019; 9(2-s):543-548
2. Montastruc, Jean-Louis, et al. "Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods." Joint Bone Spine 73.6 (2006): 629-632.
3. World Health Organization. "The importance of pharmacovigilance." (2002). (iris.who.int)
4. Pitts, P. J., Le Louet, H., Moride, Y., & Conti, R. M. (2016). 21st century pharmacovigilance: efforts, roles, and responsibilities. The Lancet Oncology, 17(11), e486-e492.
5. Zehravi, Mehrukh, Mudasir Maqbool, and Irfat Ara. "An overview about safety surveillance of adverse drug reactions and pharmacovigilance in India." The Indian Journal of Nutrition and Dietetics 58.3 (2021): 408-18.
6. Kharb P, Mittal N, Gupta MC. An evaluation of adverse drug reactions monitoring at a pharmacovigilance unit under pharmacovigilance programme of India in a tertiary care hospital of Haryana. Int J Basic Clin Pharmacol 2015;4:556-60.
7. Alomar MJ. Factors affecting the development of Adverse Drug Reactions. Saudi Pharmaceutical Journal. 2014; 22; 83-94. Available from: URL: http://ac.els-cdn.com/S1319016413000170/1-s2.0-S1319016413000170-main.pdf?_tid=89627982-2049-11e4-811f 00000aacb35fandacdnat=1407646273_e571a8a3d975a6c9751132977c8ba981
8. Alomar, M. J. (2014). Factors affecting the development of adverse drug reactions. Saudi pharmaceutical journal, 22(2), 83-94.
9. Mabanckou P (2024) Causes and Risk Factors Adverse Drug Reactions in Patients. Biochem Pharmacol. 13:369.
10. Abdullahi Rabiu Abubakar, Nordin Bin Simbak, Mainul Haque. Adverse Drug Reactions: Predisposing Factors, Modern Classifications and Causality Assessment. Research J. Pharm. and Tech. 7(9): Sept. 2014 Page 1091-1098.
11. Carnovale, C., Gentili, M., Fortino, I., Merlino, L., Clementi, E., Radice, S., & on behalf the ViGer Group. (2016). The importance of monitoring adverse drug reactions in elderly patients: the results of a long-term pharmacovigilance programme. Expert Opinion on Drug Safety, 15(2), 131-139.
12. Kumar, A. (2012). Pharmacovigilance: Importance, concepts, and processes. American Journal of Health-System Pharmacy, 74(8), 606-612.
13. Güner, Müberra Devrim, and Perihan Elif Ekmekci. "Healthcare professionals’ pharmacovigilance knowledge and adverse drug reaction reporting behavior and factors determining the reporting rates." Journal of drug assessment 8, no. 1 (2019): 13-20
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
